SCHEMBL1397151

SCHEMBL1397151

O=C(C=Cc1ccccc1)OC1CC2CCC1C2

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.62
SMN1; SMN2 Q16637 3/20 0.56
HPGD P15428 2/20 0.56
CYP2C19 P33261 1/20 0.48
BCHE P06276 1/20 0.45
KMT2A Q03164 2/20 0.44
MCL1 Q07820 1/20 0.44
CYP19A1 P11511 1/20 0.44
MAPK1 P28482 1/20 0.42
LMNA P02545 3/20 0.42
HDAC3 O15379 1/20 0.41
TNKS O95271 1/20 0.41
HDAC4 P56524 1/20 0.41
HDAC1 Q13547 1/20 0.41
HCAR2 Q8TDS4 1/20 0.41
HDAC7 Q8WUI4 1/20 0.41
HDAC2 Q92769 1/20 0.41
HDAC10 Q969S8 1/20 0.41
HDAC11 Q96DB2 1/20 0.41
HDAC8 Q9BY41 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14619688 1.00 ATM (0.62) ATMSMN1; SMN2HPGDCYP2C19BCHE
SCHEMBL2196167 0.81 SMN1; SMN2 (0.48) ATMSMN1; SMN2HPGDCYP19A1MAPK1
SCHEMBL699090 0.79 CYP2C19 (0.51) SMN1; SMN2HPGDCYP2C19BCHEKMT2A
SCHEMBL1702936 0.78 HPGD (0.48) ATMSMN1; SMN2HPGDKMT2ACYP19A1
SCHEMBL1397172 0.75 HPGD (0.46) ATMSMN1; SMN2HPGDCYP19A1MAPK1
SCHEMBL30539502 0.75 BCHE (0.55) SMN1; SMN2CYP2C19BCHEKMT2AMCL1
SCHEMBL31695293 0.74 ATM (0.71) ATMCYP19A1
SCHEMBL23707006 0.73 MAPT (0.57) SMN1; SMN2CYP2C19BCHEKMT2ALMNA
SCHEMBL28731805 0.73 KMT2A (0.51) SMN1; SMN2HPGDCYP2C19BCHEKMT2A
SCHEMBL29066462 0.73 BCHE (0.46) SMN1; SMN2HPGDCYP2C19BCHEKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3253735-B1 LATENT ACIDS AND THEIR USE BASF SE (DE) 2021-03-31 EP disclosed
US-20180009775-A1 LATENT ACIDS AND THEIR USE BASF SE (DE) 2018-01-11 US disclosed
WO-2016124493-A1 LATENT ACIDS AND THEIR USE BASF SE (DE) 2016-08-11 WO disclosed
EP-2197840-B1 SULPHONIUM SALT INITIATORS BASF SE (DE) 2013-11-06 EP disclosed
EP-2197869-B1 SULPHONIUM SALT INITIATORS BASF SE (DE) 2013-04-24 EP disclosed
EP-2197839-B1 SULPHONIUM SALT INITIATORS BASF SE (DE) 2013-01-02 EP disclosed
EP-2349993-B1 SULFONIUM DERIVATIVES AND THE USE THEROF AS LATENT ACIDS BASF SE (DE) 2012-12-12 EP disclosed
EP-2349993-A1 SULFONIUM DERIVATIVES AND THE USE THEROF AS LATENT ACIDS BASF SE (DE) 2011-08-03 EP disclosed
US-20110171569-A1 SULFONIUM DERIVATIVES AND THE USE THEROF AS LATENT ACIDS BASF SE (DE) 2011-07-14 US disclosed
EP-2288599-A1 SULFONIUM DERIVATIVES AND THE USE THEREOF AS LATENT ACIDS BASF SE (DE) 2011-03-02 EP disclosed
EP-1472576-A2 SULFONATE DERIVATIVES AND THE USE THEROF AS LATENT ACIDS Ciba SC Holding AG (CH) 2004-11-03 EP disclosed
WO-2004074242-A2 HALOGENATED OXIME DERIVATIVES AND THE USE THEREOF AS LATENT ACIDS CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 2004-09-02 WO disclosed
EP-1392675-A1 SUBSTITUTED OXIME DERIVATIVES AND THE USE THEREOF AS LATENT ACIDS Ciba SC Holding AG (CH) 2004-03-03 EP disclosed
EP-1344109-A2 ONIUM SALTS AND THE USE THEROF AS LATENT ACIDS Ciba SC Holding AG (CH) 2003-09-17 EP disclosed
WO-2003067332-A2 SULFONATE DERIVATIVES AND THE USE THEROF AS LATENT ACIDS CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 2003-08-14 WO disclosed
EP-1320785-A2 OXIME DERIVATIVES AND THE USE THEREOF AS LATENT ACIDS Ciba SC Holding AG (CH) 2003-06-25 EP disclosed
WO-2002098870-A1 SUBSTITUTED OXIME DERIVATIVES AND THE USE THEREOF AS LATENT ACIDS CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 2002-12-12 WO disclosed
WO-2002046507-A2 ONIUM SALTS AND THE USE THEROF AS LATENT ACIDS CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 2002-06-13 WO disclosed
WO-2002025376-A2 OXIME DERIVATIVES AND THE USE THEREOF AS LATENT ACIDS CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 2002-03-28 WO disclosed
US-6261738-B1 LATENT CURING CATALYSTS FOR PHOTORESISTS SUCH AS 2,2,2-TRIFLUORO-1-PHENYL-ETHANONE OXIME-O-METHYL SULFONATE CIBA SPECIALTY CHEMICALS CORPORATION 2001-07-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180009775-A1 LATENT ACIDS AND THEIR USE LTA, C1S, C9 ATM 3063/4885SMN1; SMN2 4885/4885HPGD 945/4885
US-20110171569-A1 SULFONIUM DERIVATIVES AND THE USE THEROF AS LATENT ACIDS NR2E3, HCAR3, HRH4 ATM 1725/4885SMN1; SMN2 3099/4885HPGD 3730/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.